Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.
The worldwide seroprevalence of hepatitis A virus (HAV) and hepatitis B virus (HBV) has changed over the last two decades, indicating a declining incidence of HAV and HBV infections. Therefore, vaccinations against HAV and HBV are recommended for unimmunized people before traveling to an endemic area. Unfortunately, primary antibody deficiency (PAD) patients can only obtain humoral immunity through intravenous immunoglobulin G (IVIG) replacement and not from vaccination because of a defect in antibody production. However, few studies have analyzed the titers of antibodies against HAV or HBV in IVIG products. In this study, the titers of anti-HAV and anti-HBs antibodies were measured in nineteen lots of IVIG products from five manufacturers from three countries (A, B from Korea; C, D from Japan; and E from the USA), and trough titers in plasma were estimated. Concentrations of anti-HAV antibody ranged from 1,888-8,927 mIU/mL and estimated trough titers exceeded the minimal protective value in all evaluated IVIG products. Concentrations of anti-HBs antibody ranged from 438-965 mIU/mL in products A and B and were 157, 123, and 1,945 mIU/mL in products C, D, and E, respectively. Estimated trough titers in products A, B, and E exceeded the minimal protective value but those in products C and D did not reach this threshold. These data demonstrated that available IVIG products generally provide sufficient antibodies against HAV and HBV to protect patients with PAD, although the trough concentrations of anti-HBs antibody in two IVIG products did not reach the minimum protective value.
Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea.
Soyoung
http://orcid.org/0000-0001-9627-6607
S
Lee
Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea.
Han Wool
http://orcid.org/0000-0003-3463-3060
HW
Kim
Center for Vaccine Evaluation and Study, Medical Research Institute, Ewha Womans University School of Medicine, Seoul, Korea.|Department of Pediatrics, Ewha Womans University School of Medicine, Seoul, Korea. kaykim@ewha.ac.kr.
Kyung Hyo
http://orcid.org/0000-0002-0333-6808
KH
Kim
D035922:Hepatitis A Antibodies / Q000032:analysis* / Q000097:blood; D006510:Hepatitis B Antibodies / Q000032:analysis* / Q000097:blood; D006801:Humans; D007118:Immunoassay; D016756:Immunoglobulins, Intravenous / Q000032:analysis*; D007564:Japan; D008163:Luminescent Measurements; D011933:Reagent Kits, Diagnostic; D056910:Republic of Korea; D014481:United States
D035922:Hepatitis A Antibodies; D006510:Hepatitis B Antibodies; D016756:Immunoglobulins, Intravenous; D011933:Reagent Kits, Diagnostic
Antibody; Hepatitis A Virus; Hepatitis B Virus; Intravenous Immunoglobulin